Paul Sargos(@PaulSargos) 's Twitter Profileg
Paul Sargos

@PaulSargos

☀️ Radiation Oncologist

➡️Head of Department,
Radiotherapy, Bergonie, Bordeaux, France
☀️GU and Sarcoma Team

➡️ CC-AFU
➡️ GETUG
↗️GFRU
↗️ ESTRO

ID:1053573815522021376

linkhttps://www.focus-meeting.fr/ calendar_today20-10-2018 09:09:06

4,8K Tweets

1,5K Followers

317 Following

Danny Vesprini(@dr_vesi) 's Twitter Profile Photo

The ASCENDE-SBRT trial. HDR brachy+23# EBRT vs. 5# SBRT for unfavourable prostate ca. Amazing CCTG study led by Dr. Andrew Loblaw Sunnybrook Health Sciences Centre.
Can non-invasive, cheaper high precision SBRT be used to avoid invasive brachy + GA & multiple visits ?
Shift that paradigm!

The ASCENDE-SBRT trial. HDR brachy+23# EBRT vs. 5# SBRT for unfavourable prostate ca. Amazing @CDNCancerTrials study led by @DrAndrewLoblaw @Sunnybrook. Can non-invasive, cheaper high precision SBRT be used to avoid invasive brachy + GA & multiple visits ? Shift that paradigm!
account_circle
@FOCUS_meeting(@FocusMeeting) 's Twitter Profile Photo

Notre prochain congrès approche, découvrez le meilleur moyen pour nous rejoindre ✅Lieu de la réunion
📍Espaces Vanel ; 1 Allée Chaban Delmas - Toulouse
📍 Parking Marengo
📍Métro : ligne A, station Marengo SNCF.
📍Gare : direction station métro Marengo
focus-meeting.fr

Notre prochain congrès approche, découvrez le meilleur moyen pour nous rejoindre ✅Lieu de la réunion 📍Espaces Vanel ; 1 Allée Chaban Delmas - Toulouse 📍 Parking Marengo 📍Métro : ligne A, station Marengo SNCF. 📍Gare : direction station métro Marengo focus-meeting.fr
account_circle
Drew Moghanaki(@DrewMoghanaki) 's Twitter Profile Photo

The use of SBRT for oligoprogressive cancer often increases the MILEAGE of a current line of systemic therapy. Stated differently, it can also prevent 'Systemic Therapy Escalation' Shankar Siva Puneeth Iyengar Jill Feldman pubmed.ncbi.nlm.nih.gov/34228889/

The use of SBRT for oligoprogressive cancer often increases the MILEAGE of a current line of systemic therapy. Stated differently, it can also prevent 'Systemic Therapy Escalation' @_ShankarSiva @IyengarPuneeth @jillfeldman4 #radonc pubmed.ncbi.nlm.nih.gov/34228889/
account_circle
@FOCUS_meeting(@FocusMeeting) 's Twitter Profile Photo

LE SAVIEZ-VOUS ❓

FOCUS est soutenu par les sociétés savantes impliquées en onco- urologie dont l’European Association of Urology (EAU), le YAU (filière jeune académique de l’EAU) et le Groupe d’Etude des Tumeurs Uro- Genitales (GETUG).
focus-meeting.fr

LE SAVIEZ-VOUS ❓ FOCUS est soutenu par les sociétés savantes impliquées en onco- urologie dont l’European Association of Urology (EAU), le YAU (filière jeune académique de l’EAU) et le Groupe d’Etude des Tumeurs Uro- Genitales (GETUG). focus-meeting.fr
account_circle
Journal of Clinical Oncology(@JCO_ASCO) 's Twitter Profile Photo

🚀 : STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic
🎯 Largest benefit for patients harboring a high-risk mutation Matthew P Deek Piet Ost fal.cn/3s1ch

🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer 🎯 Largest benefit for patients harboring a high-risk mutation #PCSM @matthewdeek @piet_ost fal.cn/3s1ch
account_circle
Pierre Blanchard, MD(@PBlanchardMD) 's Twitter Profile Photo

CALL FOR PAPERS: Clinical & Translational Radiation Oncology (IF 4.7) is preparing a virtual special issue on Personalized Radiation Therapy.

Deadline is October 15.

10 manuscripts will have their publication fees waived.

Your paper (original or review) is almost ready? SUBMIT to ctro.science

CALL FOR PAPERS: @ctRO_journal (IF 4.7) is preparing a virtual special issue on Personalized Radiation Therapy. Deadline is October 15. 10 manuscripts will have their publication fees waived. Your paper (original or review) is almost ready? SUBMIT to ctro.science
account_circle
Alumkal Lab(@AlumkalJoshi) 's Twitter Profile Photo

Excited to share our new work on clinical enzalutamide resistance and lineage plasticity (LP) in prostate cancer through the SU2C-PCF WCDreamTeam out now in Nature Communications!
nature.com/articles/s4146…
U-M Rogel Cancer Center, @UMichCancBio, UMich RNA Center, PCF Science, DRSN Moonshot

account_circle
European Urology(@EUplatinum) 's Twitter Profile Photo

Efficacy and Safety of Darolutamide in Patients with nmCRPC Stratified by PSADT: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial

buff.ly/3LcWC10

'In men with PSADT >6 mo (max 10 mo), darolutamide improved MFS, OS, maintened QoL, and had favorable tolerability'

Efficacy and Safety of Darolutamide in Patients with nmCRPC Stratified by PSADT: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial buff.ly/3LcWC10 'In men with PSADT >6 mo (max 10 mo), darolutamide improved MFS, OS, maintened QoL, and had favorable tolerability'
account_circle
Paul Sargos(@PaulSargos) 's Twitter Profile Photo

Sinon Air France FR, après l'annulation de mon billet pour ce vendredi, vous me proposez un retour lundi... 550 euros le billet ! 👀 honte ?
J'attends le remboursement de l'aller et du retour, comme demandé sur votre site.
Sinon, votre téléphone ne marche pas, pour info📞

Sinon @AirFranceFR, après l'annulation de mon billet pour ce vendredi, vous me proposez un retour lundi... 550 euros le billet ! 👀 honte ? J'attends le remboursement de l'aller et du retour, comme demandé sur votre site. Sinon, votre téléphone ne marche pas, pour info📞
account_circle